SCHEMBL2696545

SCHEMBL2696545

C1=CC(c2ccccc2)OC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.44
CYP2C19 P33261 6/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
RECQL P46063 1/20 0.35
MAOA P21397 7/20 0.33
MAOB P27338 7/20 0.33
KDM1A O60341 5/20 0.33
CYP2B6 P20813 3/20 0.33
SLC6A2 P23975 2/20 0.33
ADRA1A P35348 2/20 0.33
SLC6A3 Q01959 2/20 0.33
CYP1A2 P05177 2/20 0.33
CYP2D6 P10635 2/20 0.33
CYP2C9 P11712 2/20 0.33
HTR1A P08908 2/20 0.33
TAAR1 Q96RJ0 2/20 0.33
HTR2B P41595 1/20 0.33
LMNA P02545 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17754470 1.00 TSHR (0.44) TSHRCYP2C19MEN1KMT2ARECQL
SCHEMBL17754469 0.80 ALDH1A1 (0.45) TSHRMEN1KMT2ALMNAHSD17B10
SCHEMBL6397463 0.78 CHRNA7 (0.36) SLC6A2SLC6A3TAAR1HTR2BLMNA
SCHEMBL17754471 0.78 ATM (0.39) MEN1KMT2ARECQLMAOBKDM1A
SCHEMBL7100928 0.78 ATM (0.39) MEN1KMT2ARECQLMAOBKDM1A
SCHEMBL17747364 0.78 ALDH1A1 (0.34) MEN1KMT2AMAOBHTR2BLMNA
SCHEMBL17747362 0.78 ALDH1A1 (0.34) MEN1KMT2AMAOBHTR2BLMNA
SCHEMBL17754465 0.77 KDM4E (0.46) SLC6A2SLC6A3CYP2D6HTR2BCYP3A4
SCHEMBL17747346 0.75 ALDH1A1 (0.41) CYP2A6CYP2A13HSD17B10
SCHEMBL17747348 0.75 ALDH1A1 (0.41) CYP2A6CYP2A13HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12377407-B2 Compositions and methods for visible-light-controlled ruthenium-catalyzed olefin metathesis THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-08-05 US disclosed
US-20220219155-A1 Compositions And Methods For Visible-Light-Controlled Ruthenium-Catalyzed Olefin Metathesis THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2022-07-14 US disclosed
US-20220219155-A1 Compositions And Methods For Visible-Light-Controlled Ruthenium-Catalyzed Olefin Metathesis THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2022-07-14 US disclosed
US-11331656-B2 Compositions and methods for visible-light-controlled ruthenium-catalyzed olefin metathesis THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2022-05-17 US disclosed
US-11331656-B2 Compositions and methods for visible-light-controlled ruthenium-catalyzed olefin metathesis THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2022-05-17 US disclosed
EP-3864021-A1 COMPOSITIONS AND METHODS FOR VISIBLE-LIGHT-CONTROLLED RUTHENIUM-CATALYZED OLEFIN METATHESIS The Trustees of Columbia University in the City of New York (US) 2021-08-18 EP disclosed
US-20200108381-A1 Compositions And Methods For Visible-Light-Controlled Ruthenium-Catalyzed Olefin Metathesis THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2020-04-09 US disclosed
WO-2013010676-A2 SUPPORTED IONIC LIQUID PHASE CATALYST ECOLE NATIONALE SUPERIEURE DE CHIMIE DE RENNES (FR) 2013-01-24 WO disclosed
EP-1489106-B1 ARENE-RUTHENIUM COMPLEXES IMMOBILIZED ON POLYMERS, CATALYSTS CONSISTING OF THE COMPLEXES, AND PROCESSES FOR ORGANIC SYNTHESES WITH THE SAME JAPAN SCIENCE & TECH AGENCY (JP) 2012-05-09 EP disclosed
EP-1568701-B1 TRANSITION METAL COMPLEX HAVING DIPHOSPHINE COMPLEX AS LIGAND TAKEDA PHARMACEUTICAL (JP) 2010-01-20 EP disclosed
US-7348290-B2 Ring-opening or closing metathesis reaction of olefin; reduction of carbonyl compound, catalysis, complexing; cyclization, reduction JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2008-03-25 US disclosed
US-7348290-B2 Ring-opening or closing metathesis reaction of olefin; reduction of carbonyl compound, catalysis, complexing; cyclization, reduction JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2008-03-25 US disclosed
US-7348290-B2 Ring-opening or closing metathesis reaction of olefin; reduction of carbonyl compound, catalysis, complexing; cyclization, reduction JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2008-03-25 US disclosed
US-20050119416-A1 Ring-opening or closing metathesis reaction of olefin; reduction of carbonyl compound, catalysis, complexing; cyclization, reduction JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2005-06-02 US disclosed
EP-0809647-B1 CHIRAL ORGANOMETALLIC COMPOUNDS AVECIA LTD (GB) 2003-09-10 EP disclosed
US-5929266-A ZIRCONIUM, HAFNIUM, TITANIUM CYCLOPENTADIENE COMPOUNDS USEFUL IN ASYMMETRIC SYNTHESIS ZENECA LIMITED (GB) 1999-07-27 US disclosed
EP-0809647-A1 CHIRAL ORGANOMETALLIC COMPOUNDS ZENECA LIMITED (GB) 1997-12-03 EP disclosed
WO-1996025420-A1 CHIRAL ORGANOMETALLIC COMPOUNDS ZENECA LIMITED (GB) 1996-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119416-A1 Ring-opening or closing metathesis reaction of olefin; reduction of carbonyl compound, catalysis, complexing; cyclization, reduction AOX1, AOC2, POR TSHR 2898/4885CYP2C19 189/4885MEN1 2221/4885
US-11331656-B2 Compositions and methods for visible-light-controlled ruthenium-catalyzed olefin metathesis PPOX, CYBA, CYBB TSHR 4806/4885CYP2C19 883/4885MEN1 1935/4885
US-12377407-B2 Compositions and methods for visible-light-controlled ruthenium-catalyzed olefin metathesis PPOX, CYBA, CYBB TSHR 4806/4885CYP2C19 883/4885MEN1 1935/4885
US-20220219155-A1 Compositions And Methods For Visible-Light-Controlled Ruthenium-Catalyzed Olefin Metathesis PPOX, CYBA, CYBB TSHR 4806/4885CYP2C19 883/4885MEN1 1935/4885
US-20200108381-A1 Compositions And Methods For Visible-Light-Controlled Ruthenium-Catalyzed Olefin Metathesis PPOX, CYBA, CYBB TSHR 4806/4885CYP2C19 883/4885MEN1 1935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.